Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Gold You Said

Gold Seeker Tuesday, 04/15/14 01:44:46 PM
Re: vester_guy post# 20778
Post # of 20780
Wolfie, what makes you think the UNI agreement is currently not in force? There were indeed a SEC filing stating the GCDx agreement was cancelled but nothing has been filed to cancel the UNI agreement. In fact, there are several websites in SE Asia that are selling Onko Sure distributed by UNI.

What would be your proof that the agreement was never finalized? Dreams? Magic crystal ball? Imagination?


Gold Said

In fact, there are several websites in SE Asia that are selling Onko Sure distributed by UNI.


Columbo Says

Remember this Agreement Gold? You forgot to mention in your last post...Do you think that is why Onko Sure is continuing to be distributed as you stated...? Here is why Uni Pharma is still distributing Onko Sure>>>>


Marketwired
Radient Pharmaceuticals Corporation August 4, 2011 7:00 AM

TUSTIN, CA--(Marketwire -08/04/11)- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC.PK - News) (Pinksheets: RXPC.PK - News), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has entered into an exclusive distribution agreement with Taiwan-based Uni Pharma, Co. Ltd. Uni Pharma will import, market, and sell Onko-Sure® in the Taiwanese market.

Onko-Sure® is a simple, non-invasive cancer blood test which has received regulatory approval in Taiwan as a general cancer tumor marker. Onko-Sure® is also approved as a general cancer tumor marker in several other Asian markets, as well as the European Union. The US FDA has cleared Onko-Sure® to market for monitoring colorectal cancer during treatment and for post-treatment recurrence monitoring. Onko-Sure® has also received regulatory approval for sale in Canada for lung cancer detection, treatment and recurrence monitoring.

"Having already built some traction in the Taiwanese market for Onko-Sure®, we are pleased to enter into this agreement with a partner like Uni Pharma. They have built well-established distribution and sales channels into doctors' offices, labs, and hospitals," stated Radient's Chairman and CEO, Mr. Douglas MacLellan.

Uni Pharma's General Manager, Mr. Terry Lin added, "Onko-Sure® is exactly what we were looking for in a high-value cancer diagnostic backed by strong clinical data from different clinical trial sites throughout the world. Our sales team has already received training in the U.S. from Radient's science and marketing executives. We've hired a Product Manager for Onko-Sure® who will focus exclusively on the marketing and sale of Onko-Sure®. We are excited and look forward to a successful launch throughout Taiwan."

About Uni Pharma:
Founded in 1998, Uni Pharma was established by a group of professional managers with multi-national pharmaceutical company backgrounds and extensive experience in the pharmaceutical industry. Uni Pharma is dedicated to supplying the best products to patients and delivering the most value to its partners. Uni Pharma distributes pharmaceutical and medical device products in Taiwan for nine international firms from seven countries across the globe. For more information please visit http://www.uni-pharma.com/gyhyenglish.html.



http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2457187542.html